pc-1

Hexa-D-arginine 是稳定的furin 抑制剂，能够作用于 furin (Ki:106 nM)、PACE4 (Ki:580 nM)、PC1 (Ki:13.2 nM)。它在体外和体内均可阻断假单胞菌外毒素 A 和炭疽毒素的毒性。

TPC-144 is a potent and selective LSD1 inhibitor with a reversible inhibition mechanism. TPC-144 has antitumor activity in several human AML and SCLC cell lines and xenograft models.

VPC-13163 (NSC-52361) 对 LNCaP 和耐恩杂鲁胺的前列腺癌细胞系 (MR49F) 具有很强的抗增殖活性，而它不影响 AR 独立 PC3 细胞系的生长。它还抑制 LNCaP 和 MR49F 中的前列腺特异性抗原 (PSA) 并降低 AR 靶基因 PSA 和 TMPRSS2 的表达。这些发现表明 VPC-13566 表现出 AR BF3 特定的作用机制。

OPC-14523 hydrochloride (VPI 013 hydrochloride) 是一种具有口服活性和高效性的 sigma 和 5-HT1A 受体激动剂，具有抗抑郁活性，可用于研究神经系统疾病。

OPC-14523, a 5-HT1A receptor agonist, is used potentially for the treatment of depression and neuropathic pain.

VPC-13566 是一种 BF3 特异性小分子，可有效抑制雄激素受体转录活性并从 BF3 口袋中置换出 BAG1L 肽。 VPC-13566 抑制各种前列腺癌细胞系的生长，并减少小鼠中 AR 依赖性前列腺癌异种移植肿瘤的生长。

VPC-18005 是一种荧光素酶抑制剂。 VPC-18005 抑制 ERG 诱导的转录并直接与 ERG-ETS 结构域相互作用，从而破坏 ERG 与 DNA 的结合。

OPC-167832 is a potent and orally active dprE1 Inhibitor with an IC50 of 0.258 μM. OPC-167832 has antituberculosis activity and can be used for the research of tuberculosis caused by Mycobacterium tuberculosis[1]. OPC-167832 exhibits very low MICs against laboratory strains of M. tuberculosis H37Rv (MIC: 0.0005 μg ml) and Kurono (MIC: 0.0005 μg ml) and strains with monoresistance to rifampin (RIF), isoniazid (INH), ethambutol (EMB), streptomycin (STR), and pyrazinamide (PZA) (MIC: 0.00024-0.001 μg ml). However, OPC-167832 has minimal or no activity against standard strains of nonmycobacterial aerobic and anaerobic bacteria[1].The IC90 values of OPC-167832 against intracellular M. tuberculosis strains H37Rv and Kurono are 0.0048 and 0.0027 μg ml, respectively. OPC-167832 shows bactericidal activity against intracellular M. tuberculosis at a low concentration, and the bactericidal activity is saturated at concentrations of 0.004 μg ml or higher[1]. OPC-167832 (oral administration; 0.625-10 mg kg) exhibits a good pharmacokinetic characteristic. The plasma reaches peak at 0.5 h to 1.0 h (tmax) and is eliminated with a half-life (t1 2) of 1.3 h to 2.1 h OPC-167832 distribution in the lungs is approximately 2 times higher than that in plasma, and the Cmax and AUCt of OPC-167832 in plasma and the lungs shows dose dependency[1].OPC-167832 (oral administration; 0.625-10 mg kg; 4 weeks) significantly reduces lung CFU compared to the vehicle group. The dose-dependent decrease of lung CFU is observed from 0.625 mg kg to 2.5 mg kg. In a M. tuberculosis Kurono-infected ICR female mice model. OPC-167832 combines with DMD, BDQ, or LVX via oral gavage exhibits significantly higher efficacies than each single agent alone[1].[1].OPC-167832 (oral gavage; 2.5 mg kg; combination with DCMB; 12 weeks) demonstrates the most potent efficacy when compares with DC, DCB. The lung CFU count after 6 weeks of treatment is below the detection limit, and at the end of just 8 weeks of treatment, the bacteria in the lungs of all the evaluated mice had already been eradicate[1]. [1]. Norimitsu Hariguchi, et al. OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor.Antimicrob Agents Chemother. 2020 May 21;64(6):e02020-19.

VPC-13789 is a highly potent, selective, and orally bioavailable antiandrogen compound that shows promise for studying and developing therapeutics for castration-resistant prostate cancer (CRPC). In LNCaP cells, VPC-13789 effectively inhibits the transcriptional activity of the androgen receptor (AR) with an IC50 value of 0.19 μM [1].

VPC-14228 是一种特异性 AR-DBD 抑制剂，通过抑制 Y594A 和 Q592A 突变体起作用。

VPC-16606 is a potent and selective inhibitor of ERα-dependent cell growth and gene expression. VPC-16606 prevents the interaction between ERα-LBD and SRC-3 fusion proteins in a dose-dependent manner.

OPC-163493 是一种口服活性的肝脏靶向线粒体解偶联剂，能够减少 Δψ 及线粒体 ROS 生成。它展现了抗糖尿病与心血管益处，可在中风 高血压大鼠模型中降低血压、延长存活时间并改善肾脏功能。

SPC-180002是一种针对SIRT1 3的双重抑制剂，IC50值分别为1.13 μM和5.41 μM。该化合物可通过诱导ROS产生干扰氧化还原平衡，进而增强p21蛋白的稳定性并引起线粒体功能障碍，同时显著抑制细胞周期进程及癌细胞的增殖，并能激活Nrf2信号通路。

NPC-16731 is a Bradykinin antagonist.

NPC-15437 (盐酸盐) 是一种 PKC 的选择性抑制剂，与酶的调节域相互作用。

NPC-14695 is a smooth muscle-selective muscarinic antagonist with bronchodilating activity.

VPC-14449 是一种具有选择性的雄激素受体 DNA 结合结构域 (AR-DBD) 抑制剂，可用于研究前列腺癌。

Ppc-1 is a chemical compound known for its inhibitory effects on the Gram-negative periodontopathogen Porphyromonas gingivalis. It acts as a mitochondrial uncoupler, enhancing mitochondrial oxygen consumption without affecting ATP production. Additionally, Ppc-1 serves as a cell-permeate inhibitor of interleukin-2 (IL-2). This compound exhibits various beneficial activities, including anti-obesity, antibacterial, and anti-inflammatory properties.

NPC-18915 is a benzofuran compound, inhibitor of neutophil activation.

Sorafenib (Bay 43-9006) 是一种多激酶抑制剂，抑制 Raf-1、B-Raf、VEGFR2、VEGFR3、VEGFR4、PDGFRβ、FLT3、c-Kit 等 (IC50=6 22 90 15 20 20 57 58 nM)，具有口服活性。Sorafenib 具有抗肿瘤活性，可以诱导细胞自噬和凋亡，也可以激动铁死亡。

RMC-9805 是一种新颖的突变选择性的共价口服的 KRASG12D(ON) 抑制剂。RMC-9805、KRASG12D 和 cyclophilin A 之间形成稳定、高亲和力的三重复合物，通过破坏其与下游效应器的相互作用，抑制 KRASG12D(ON) 下游的信号传导。RMC-9805 可以诱导 KRASG12D 肿瘤临床前模型中的细胞凋亡并促进肿瘤消退。凭借在化合物合成方面的丰富经验，我们可以根据您的研究需求为该产品提供快速定制合成服务。

Vorinostat (SAHA) 是一种泛的组蛋白脱乙酰酶 (HDAC) 抑制剂 (IC50=10 nM)，对 HDAC1 2 3 6 7 11 均有抑制活性。 Vorinostat 具有抗肿瘤活性，可以诱导细胞分化，阻滞细胞周期，诱导细胞凋亡。

Defactinib (VS-6063) 是一种 FAK 的第二代抑制剂，抑制 FAK 在 Tyr397 位点磷酸化。Defactinib 具有潜在抗肿瘤活性。

Stattic (STAT3 Inhibitor V) 是一种 STAT3 抑制剂 (IC50=5.1 μM)，选择性地抑制 STAT3 活化、二聚化和核转位。Stattic 具有抗肿瘤活性，可诱导细胞凋亡。